Guía detallada disponible en inglés. MFMD ofrece orientación y coordinación del centro en español.
Treat a new peptide program as a new clinical service line — not as a new SKU. Before marketing or selling it, define the clinical purpose, responsible prescriber, patient-evaluation pathway, pharmacy/source, staffing model, documentation, monitoring, escalation, and implementation plan. Business opportunity can start the discussion; it should not replace clinical review.
Abrir la explicación completa3 secciones y fuentes primarias
What is a practical sequence for adding a peptide or longevity line?
Define the business objective; identify the exact therapy (substance, formulation, route, source) rather than “we want to add peptides”; review the clinical and pharmacy framework (evidence, safety, sourcing, prescribing, patient selection); build the operating model (who does what, documentation, medication handling, monitoring, escalation); review clinic fit (space, training, workflow, AHCA/insurance impact); then prepare for launch.
MFMD’s service-line development role
MFMD helps an existing brick-and-mortar practice evaluate and structure the clinical side of the business opportunity — service concept review, clinical feasibility, governance structure, prescribing and staffing model, pharmacy/sourcing considerations, documentation and escalation framework, implementation planning, and physician review before launch. This is clinical service-line development and business development, not AHCA licensure consulting.
Owner takeaway
Build the service line before you build the marketing campaign. See Add a Service Line to start.